Deciphex, a developer of Pathology AI solutions, announced the appointment of Pierre Moulin, MD, PhD, MBA, as its new chief scientific officer (CSO). Moulin has established himself as a distinguished physician-scientist and pathologist, with a specialist interest in the realms of data science and artificial intelligence in pathology, the company says.

Pierre has previously held senior research positions for top pharmaceutical companies, and has been a key initiator of the IMI BigPicture project along with serving as an attending pathologist and lecturer at CHUV and the University of Basel, the company says. 

As part of his experience, he has previously led the development of a pathology unit focused on adverse event mechanisms and made substantial contributions to enhancing clinical trials through his unique integration of molecular profiling, digital pathology, image analysis, and artificial intelligence; improving their efficiency and precision. As a key initiator of the BigPicture project, Moulin has managed large-scale, collaborative initiatives, bringing together various experts to advance better access to pathology data for AI researchers, Deciphex says.

Further reading: November/December 2023 Tech Guide: Anatomic and Digital Pathology Instruments and Tools

“I have long admired Deciphex’s work at the forefront of pathology AI and am consistently impressed by their outstanding collection of talent,” says Moulin. “We share a common vision, one that aims at driving the future of pathology by incorporating AI in both clinical practice and clinical trials. It’s an honor to be a part of this endeavor.”

Moulin’s leadership is expected to accelerate the company’s AI research and development program, and expand its impact in supporting clinical trials, the company says.

“Bringing Dr. Moulin on board is a strategic move that strengthens our commitment to being leaders in Pathology AI,” says Donal O’Shea, PhD, CEO of Deciphex. “His extensive experience and innovative approach in digital pathology are aligned with our goals to enhance clinical trial methodologies and improve patient outcomes.”